Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

<p>Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving merestinib + LY2874455 in Cohort 2 (n=8, red line). G...

Ամբողջական նկարագրություն

Պահպանված է:
Մատենագիտական մանրամասներ
Հիմնական հեղինակ: Evan C. Chen (15054014) (author)
Այլ հեղինակներ: Helen Gandler (15054017) (author), Isidora Tošić (15054020) (author), Geoffrey G. Fell (15054023) (author), Ashlee Fiore (15054026) (author), Olga Pozdnyakova (15054029) (author), Daniel J. DeAngelo (15031959) (author), Ilene Galinsky (15054032) (author), Marlise R. Luskin (15054035) (author), Martha Wadleigh (15054038) (author), Eric S. Winer (15054041) (author), Rebecca Leonard (15054044) (author), Kelsey O'Day (15054047) (author), Adrienne de Jonge (15054050) (author), Donna Neuberg (15038318) (author), A. Thomas Look (14951403) (author), Richard M. Stone (15054053) (author), David A. Frank (14961075) (author), Jacqueline S. Garcia (15043140) (author)
Հրապարակվել է: 2025
Խորագրեր:
Cancer
Therapeutic Research and Development
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Protein kinase & phosphatase drug targets
Hematological Cancers
Leukemias
Pharmacology
Pharmacokinetics and pharmacodynamics
Precision Medicine
Small Molecule Agents
Kinase inhibitors
Translational Research
Ցուցիչներ: Ավելացրեք ցուցիչ
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
Նկարագրություն
Ամփոփում:<p>Pharmacokinetic analysis of merestinib and LY2874455. A, Merestinib plasma levels were measured at the time points shown and compared between patients receiving single-agent merestinib in Cohort 1 (n=7, black line) and patients receiving merestinib + LY2874455 in Cohort 2 (n=8, red line). Geometric mean is displayed. Error bars denote standard error. * signifies p < 0.05. B, Plasma levels of merestinib (first column) and its metabolites LSN2800870 and LSN2887652 (second and third columns, respectively) in patients receiving merestinib monotherapy (first row) and merestinib + LY2874455 (second row). C, Plasma levels of LY2874455 in patients receiving merestinib + LY2874455. Abbreviations: Cohort 1 = patients receiving single-agent merestinib; Cohort 2 = patients receiving merestinib + LY2874455.</p>

Նմանատիպ նյութեր